Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Discovery of the Potent and Highly Selective PARP7 Inhibitor as a Novel Immunotherapeutic Agent for Tumors
Hong‐Feng Gu, Wenxin Yan, Yong Wang, et al.
Journal of Medicinal Chemistry (2022) Vol. 66, Iss. 1, pp. 473-490
Closed Access | Times Cited: 23

Showing 23 citing articles:

Design, Synthesis, and Structure–Activity Relationship of Novel Pyridazinone-Based PARP7/HDACs Dual Inhibitors for Elucidating the Relationship between Antitumor Immunity and HDACs Inhibition
Ji‐Long Duan, Chenchen Wang, Yinghui Yuan, et al.
Journal of Medicinal Chemistry (2024) Vol. 67, Iss. 6, pp. 4950-4976
Closed Access | Times Cited: 32
Targeting Arginine Methyltransferase PRMT5 for Cancer Therapy: Updated Progress and Novel Strategies
Jiahong Zheng, Bang Li, Yingqi Wu, et al.
Journal of Medicinal Chemistry (2023) Vol. 66, Iss. 13, pp. 8407-8427
Closed Access | Times Cited: 35
Parps in immune response: Potential targets for cancer immunotherapy
S Wang, Jingling Huang, T. X. Zeng, et al.
Biochemical Pharmacology (2025) Vol. 234, pp. 116803-116803
Closed Access | Times Cited: 1
Loss of Parp7 increases type I interferon signalling and reduces pancreatic tumour growth by enhancing immune cell infiltration
Vinicius Kannen, Marit Rasmussen, Siddhartha Das, et al.
Frontiers in Immunology (2025) Vol. 15
Open Access
PARP7 as a new target for activating anti-tumor immunity in cancer
K. Popova, Johannes Benedum, Magdalena Engl, et al.
EMBO Molecular Medicine (2025)
Open Access
Loss of PARP7 Increases Type I Interferon Signaling in EO771 Breast Cancer Cells and Prevents Mammary Tumor Growth by Increasing Antitumor Immunity
Marit Rasmussen, Karoline Alvik, Vinicius Kannen, et al.
Cancers (2023) Vol. 15, Iss. 14, pp. 3689-3689
Open Access | Times Cited: 12
Recent contributions of pyridazine as a privileged scaffold of anticancer agents in medicinal chemistry: An updated review
Ziqiang Liu, Qian Zhang, Yulin Liu, et al.
Bioorganic & Medicinal Chemistry (2024) Vol. 111, pp. 117847-117847
Closed Access | Times Cited: 4
Immunomodulatory roles of PARPs: Shaping the tumor microenvironment, one ADP-ribose at a time
Deja M. Brooks, Sudarshan Anand, Michael S. Cohen
Current Opinion in Chemical Biology (2023) Vol. 77, pp. 102402-102402
Open Access | Times Cited: 9
Discovery of tricyclic PARP7 inhibitors with high potency, selectivity, and oral bioavailability
Juan Xu, Anmin Zhao, Danni Chen, et al.
European Journal of Medicinal Chemistry (2024) Vol. 266, pp. 116160-116160
Closed Access | Times Cited: 3
Discovery of Highly Selective PARP7 Inhibitors with a Novel Scaffold for Cancer Immunotherapy
Hong‐Feng Gu, Wenxin Yan, Jieping Yang, et al.
Journal of Medicinal Chemistry (2023) Vol. 67, Iss. 3, pp. 1932-1948
Closed Access | Times Cited: 8
Small molecule tractable PARP inhibitors: Scaffold construction approaches, mechanistic insights and structure activity relationship
Amandeep Thakur, Mandeep Rana, Ritika Ritika, et al.
Bioorganic Chemistry (2023) Vol. 141, pp. 106893-106893
Closed Access | Times Cited: 7
Emerging Targets and Therapeutics in Immuno-Oncology: Insights from Landscape Analysis
Kavita A. Iyer, Julian Ivanov, Rumiana Tenchov, et al.
Journal of Medicinal Chemistry (2024) Vol. 67, Iss. 11, pp. 8519-8544
Open Access | Times Cited: 2
Targeting selective inhibitors of PARPs in drug discovery and development
Maolin Duan, Jing Gao, Jiajin Li, et al.
Medicinal Chemistry Research (2024) Vol. 33, Iss. 10, pp. 1734-1756
Closed Access | Times Cited: 2
PARP enzymes and mono-ADP-ribosylation: advancing the connection from interferon-signalling to cancer biology
Barbara Morone, Giovanna Grimaldi
Expert Reviews in Molecular Medicine (2024) Vol. 26
Open Access | Times Cited: 2
Privileged Scaffolds for Potent and Specific Inhibitors of Mono-ADP-Ribosylating PARPs
Maria Giulia Nizi, Chiara Sarnari, Oriana Tabarrini
Molecules (2023) Vol. 28, Iss. 15, pp. 5849-5849
Open Access | Times Cited: 4
Discovery of highly potent PARP7 inhibitors for cancer immunotherapy
Jieping Yang, Beibei Liu, Wenxin Yan, et al.
Bioorganic Chemistry (2024) Vol. 148, pp. 107469-107469
Closed Access | Times Cited: 1
Biological Functions and Therapeutic Potential of NAD+ Metabolism in Gynecological Cancers
Subin Myong, Anh Nguyen, Sridevi Challa
Cancers (2024) Vol. 16, Iss. 17, pp. 3085-3085
Open Access | Times Cited: 1
New TIPARP inhibitor rescues mitochondrial function and brain injury in ischemic stroke
Yang Cai, Hong‐Feng Gu, Lu Li, et al.
Pharmacological Research (2024), pp. 107508-107508
Open Access | Times Cited: 1
Prudent tactics to sail the boat of PARP inhibitors as therapeutics for diverse malignancies
Mandeep Rana, Amandeep Thakur, Charanjit Kaur, et al.
Expert Opinion on Drug Discovery (2023) Vol. 18, Iss. 10, pp. 1169-1193
Closed Access | Times Cited: 2
Exploring the structural-activity relationship of hexahydropyrazino[1,2-d]pyrido[3,2-b][1,4]oxazine derivatives as potent and orally-bioavailable PARP7 inhibitors
Silong Zhang, Yu Zhang, Ziwei Wang, et al.
European Journal of Medicinal Chemistry (2023) Vol. 261, pp. 115836-115836
Closed Access | Times Cited: 2
ADP-ribosylation: An emerging direction for disease treatment
Yuting Liu, Yan Che, Hong-liang Qiu, et al.
Ageing Research Reviews (2023) Vol. 94, pp. 102176-102176
Closed Access | Times Cited: 2
Screening and design of PARP12 inhibitors from traditional Chinese medicine small molecules using computational modeling and simulation
Xiaochen Yang, Baolin Liu, Aamir Mehmood, et al.
Journal of Biomolecular Structure and Dynamics (2024), pp. 1-14
Closed Access
Unraveling the inhibitory potential of Rosetta designed de novo cyclic peptides on PARP7 through molecular dynamics simulations
Yuqi Zhu, Aamir Mehmood, Daixi Li
New Journal of Chemistry (2024) Vol. 48, Iss. 16, pp. 7347-7355
Closed Access
Page 1

Scroll to top